View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsDanimer Scientific 配当と自社株買い配当金 基準チェック /06Danimer Scientific配当金を支払った記録がありません。主要情報n/a配当利回り-755.7%バイバック利回り総株主利回り-755.7%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 18+ 1 more updateBidding Procedure Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the bidding procedures relating to the sale of the substantially all the assets of Danimer Scientific, Inc. on April 17, 2025. The Court approved for the sale of substantially all the assets to the successful bidder through auction. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. If the debtor receives any qualified bids, then it would hold an auction for its assets on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.お知らせ • Apr 15Motion for sale of De Minimis Asset Sale Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the sale procedures relating to the sale of De Minimis assets of Danimer Scientific, Inc on April 14, 2025. As per the order the debtors is authorized to sell de minimis assets for $0.25 million or less in total consideration or value in one or a series of related transactions without further notice or court approval after providing notice of the sale to certain parties in accordance with the following procedures. With regard to a De Minimis transaction with a net selling price less than or equal to $2 million, the debtor shall give written notice of each de Minimis transaction to notice parties. The sale notice shall be filed and sent to the notice parties by e-mail, facsimile, or first-class mail at least 7 business days prior to the closing of such de Minimis transaction. With regard to a De Minimis Transaction with a selling price of greater than $2 million, the debtor shall give a sale notice to the notice parties and all other parties required receiving notice under Bankruptcy Rule 2002(a) (2). The sale notice shall be filed and sent to the 2002 parties by e-mail, facsimile, or first-class mail at least 7 calendar days prior to the closing of such de Minimis transaction. Any objections to the De Minimis Transaction must be in writing, state the grounds for the objection with specificity, and be filed and served so as to be actually received on or before the Closing Date. If a sale objection is properly filed and served by the sale objection deadline, and the debtor and the objecting party are unable to reach an agreement among themselves, then the relevant de Minimis asset shall be sold or otherwise transferred only upon further order of this court, after notice and a hearing; provided, however, that the debtor, with the agreement of the relevant proposed counterparty, may consummate any portion of the de Minimis transaction that is not the subject of a sale objection on or after the expiration of the sale objection deadline. If no sale objection is properly filed and served by the sale objection deadline, then the debtor, without further order of the court, is authorized, but not directed, to consummate the de Minimis transaction immediately, and take such other actions as necessary to close such transaction and collect the proceeds thereof.お知らせ • Mar 28Motion for Asset Sale Filed by Danimer Scientific, Inc.Danimer Scientific, Inc filed a motion in the US Bankruptcy Court for the sale of its substantially all its assets on March 27, 2025. The debtor seeks the Court’s approval for the sale of its substantially all its assets to successful bidder. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. The debtor has scheduled an auction on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.お知らせ • Mar 19+ 1 more updateMotion for Joint Administration Filed by Danimer Scientific, Inc.Danimer Scientific, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on March 18, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Danimer Bioplastics, Inc., Danimer Scientific Holdings, LLC, Danimer Scientific Kentucky, Inc., Danimer Scientific Manufacturing, Inc., Danimer Scientific, L.L.C. Meredian Bioplastics, Inc., Meredian Holdings Group, Inc., Meredian, Inc. and Novomer, Inc., with its own case for administrative and procedural purposes. Danimer Scientific, Inc. has been proposed as the lead debtor.お知らせ • Dec 18Danimer Scientific, Inc. announced that it expects to receive $11.25 million in fundingDanimer Scientific, Inc. announced that it has entered into a super senior secured uninsured promissory note agreement with certain lenders under its existing term loan financing agreement, as well as certain additional lenders for a secured loan for a principal amount of $11,250,000 in exchange for cash, net of a 5% upfront fee and other fees and expenses on December 17, 2024. The secured loan matures on December 17, 2026, and accrues interest at 15% per annum, which interest shall be paid in kind on a quarterly basis. Prepayment of the secured loan is subject to payment of premiums of (i) prior to December 17, 2025, 30% and (ii) on or after December 17, 2025, and before maturity, 10%.お知らせ • Dec 04Danimer Scientific, Inc. Announces Resignation of Cynthia Cohen as A DirectorDanimer Scientific, Inc. announced that effective as of December 1, 2024, Cynthia Cohen resigned as a director of the Company. Ms. Cohen’s resignation was not because of any disagreement with the Company.お知らせ • Nov 16Danimer Scientific, Inc. announced delayed 10-Q filingOn 11/15/2024, Danimer Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 05Danimer Scientific Announces Intention to Complete a Reverse Stock Split to Regain Compliance with the Price Criteria of Section 802.01C of the NYSE Listed Company ManualDanimer Scientific, Inc. announced that, following approval by the Company's stockholders and its Board of Directors, the Company will effect a reverse stock split ('Reverse Stock Split') of Danimer's Class A common stock, par value $0.0001 per share ('Common Stock'), at a ratio of 1-for-40 (the 'Reverse Stock Split Ratio'), which ratio was determined by the Board of Directors from within a range of ratios authorized by the stockholders. The Reverse Stock Split is expected to become effective on November 12, 2024, after close of trading on the New York Stock Exchange ('NYSE'). The Common Stock is expected to begin trading on a split-adjusted basis when the markets open on November 13, 2024, under the existing trading symbol 'DNMR' and new CUSIP number (236272 407). The Company believes the Reverse Stock Split will increase the price per share of the Common Stock and thus enable it to regain compliance with the price criteria of Section 802.01C of the NYSE Listed Company Manual (the 'Minimum Share Price Rule').Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Special Advisor & Director Stephen Croskrey was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 28Danimer Scientific Announces Second Circuit Court Affirms Dismissal of Class Action LawsuitDanimer Scientific, Inc. announced that, on September 27, 2024, the United States Court of Appeals for the Second Circuit affirmed the 2023 Order of the United States District Court for the Eastern District of New York dismissing a previously disclosed putative class action complaint captioned In re Danimer Scientific, Inc. Securities Litigation. Subsequently, the plaintiffs in the three shareholder derivative cases that had been pending in state and federal courts in Delaware, which cases had been stayed pending the outcome of the Second Circuit case, dismissed their complaints.お知らせ • Oct 15+ 2 more updatesDanimer Scientific, Inc. to Report Q3, 2024 Results on Nov 14, 2024Danimer Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 14, 2024Price Target Changed • Sep 14Price target decreased by 25% to US$0.85Down from US$1.13, the current price target is an average from 4 analysts. New target price is 115% above last closing price of US$0.40. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.81 next year compared to a net loss per share of US$1.52 last year.New Risk • Sep 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$66m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$59m net loss in 3 years). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$39.7m market cap).Major Estimate Revision • Aug 15Consensus revenue estimates decrease by 44%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$74.0m to US$41.7m. EPS estimate increased from -US$0.885 to -US$0.785 per share. Chemicals industry in the US expected to see average net income growth of 40% next year. Consensus price target down from US$1.41 to US$1.13. Share price fell 20% to US$0.37 over the past week.Price Target Changed • Aug 12Price target decreased by 12% to US$1.33Down from US$1.51, the current price target is an average from 5 analysts. New target price is 237% above last closing price of US$0.39. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.79 next year compared to a net loss per share of US$1.52 last year.Reported Earnings • Aug 09Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: US$0.20 loss per share (improved from US$0.39 loss in 2Q 2023). Revenue: US$7.63m (down 41% from 2Q 2023). Net loss: US$22.7m (loss narrowed 42% from 2Q 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in the US.お知らせ • Aug 09Danimer Scientific, Inc. Provides Financial Guidance for the Second Quarter of Fiscal 2025Danimer Scientific, Inc. provides financial guidance for the second quarter of fiscal 2025. For the period, the company expects annualized PHA revenues to more than triple, based solely on demand from existing customer relationships and their indicated volumes, including the aforementioned 20-million-pound cutlery award.お知らせ • Aug 02Danimer Scientific, Inc. to Report Q2, 2024 Results on Aug 08, 2024Danimer Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024お知らせ • Jun 13+ 14 more updatesDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value IndexDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value Indexお知らせ • May 25Danimer Scientific, Inc. Receives Non-Compliance Notice from NYSE RegulationOn May 21, 2024, Danimer Scientific, Inc. (the Company") was notified by NYSE Regulation (NYSER") that the Company is not in compliance with the New York Stock Exchange's (NYSE") continued listing criteria under Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period as of May 20, 2024. The Company has notified the NYSE of its intent to cure the deficiency and return to compliance with the NYSE continued listing requirements. The Company will return to compliance if, during the six-month period following receipt of the NYSE notice, on the last trading-day of any calendar month, the Company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under NYSE rules, the Company's common stock will continue to be traded on the NYSE during this period, subject to the Company's compliance with other applicable continued listing requirements. The NYSER notification does not affect the Company's business operations, Securities and Exchange Commission reporting requirements or debt obligations.Price Target Changed • May 22Price target decreased by 10% to US$1.41Down from US$1.57, the current price target is an average from 5 analysts. New target price is 84% above last closing price of US$0.76. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$0.89 next year compared to a net loss per share of US$1.52 last year.分析記事 • May 21News Flash: Analysts Just Made A Substantial Upgrade To Their Danimer Scientific, Inc. (NYSE:DNMR) ForecastsShareholders in Danimer Scientific, Inc. ( NYSE:DNMR ) may be thrilled to learn that the analysts have just delivered a...Major Estimate Revision • May 14Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$78.3m to US$60.9m. Forecast losses increased from -US$0.91 to -US$0.92 per share. Chemicals industry in the US expected to see average net income growth of 34% next year. Consensus price target of US$1.51 unchanged from last update. Share price was steady at US$0.80 over the past week.分析記事 • May 10Danimer Scientific, Inc. (NYSE:DNMR) Analysts Are Cutting Their Estimates: Here's What You Need To KnowDanimer Scientific, Inc. ( NYSE:DNMR ) shareholders are probably feeling a little disappointed, since its shares fell...New Risk • May 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$68m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$68m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (US$93.7m market cap).Reported Earnings • May 08First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: US$0.26 loss per share (improved from US$0.36 loss in 1Q 2023). Revenue: US$10.2m (down 14% from 1Q 2023). Net loss: US$27.3m (loss narrowed 26% from 1Q 2023). Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 1.3%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in the US.お知らせ • May 07Danimer Scientific Reveals New Branding and New Applications Based on PHA During NPE 2024Danimer Scientific, Inc. is unveiling new commercial applications and branding during NPE 2024, North America’s large plastics tradeshow, taking place this week in Orlando, FL. A more perfect polymer™ takes center stage at NPE 2024. Danimer’s signature PHA, Nodax®, represents a more perfect polymer revolution. PHAs (polyhydroxyalkanoates) are naturally made polymer chains, and at Danimer it harness microbes as tiny reactors to make its biopolymers, using canola oil as the renewable feedstock. The resulting PHA can be used to replace conventional plastics in uses from straws to lids, from coffee pods to flexible packaging, and from paper coatings to adhesives. With full PHA production capability in place, Danimer is poised for significant growth with commercial partners for several applications, including cutlery, flexible food packaging and paper packaging barrier coatings. Microbes, not Microplastics™ enables a new future for packaging items. Danimer is committed to offering solutions to address plastic pollution and the proliferation of microplastics. It is all about the microbes, both during origination and biodegradation. Microbes produce PHAs, and microbes biochemically recycle its PHAs, whether in industrial compost, home compost, soils, fresh water or the marine environment. Because a large class of microbes present in natural systems readily identify PHAs as a food source, there is no threat of residual microplastics. PHA grades are third party certified to fully biodegrade under various conditions, with the added benefit of no ecotoxicity concerns, PFAS or regulated metals. That makes Nodax a more perfect polymer™ for its planet.お知らせ • May 05Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024.お知らせ • May 03Danimer Scientific, Inc. to Report Q1, 2024 Results on May 07, 2024Danimer Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024分析記事 • Apr 25Broker Revenue Forecasts For Danimer Scientific, Inc. (NYSE:DNMR) Are Surging HigherDanimer Scientific, Inc. ( NYSE:DNMR ) shareholders will have a reason to smile today, with the analysts making...Major Estimate Revision • Apr 23Consensus revenue estimates increase by 11%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$70.3m to US$78.3m. EPS estimate unchanged from -US$0.91 at last update. Chemicals industry in the US expected to see average net income growth of 27% next year. Consensus price target down from US$1.57 to US$1.51. Share price rose 2.6% to US$0.80 over the past week.New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (US$98.6m market cap).Major Estimate Revision • Apr 05Consensus revenue estimates decrease by 25%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$95.8m to US$72.0m. EPS estimate increased from -US$1.42 to -US$0.81 per share. Chemicals industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$2.57 to US$2.02. Share price fell 3.7% to US$1.05 over the past week.Price Target Changed • Apr 02Price target decreased by 14% to US$2.22Down from US$2.57, the current price target is an average from 5 analysts. New target price is 109% above last closing price of US$1.06. Stock is down 76% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$1.52 last year.Reported Earnings • Apr 01Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$1.52 loss per share (improved from US$1.78 loss in FY 2022). Revenue: US$46.7m (down 12% from FY 2022). Net loss: US$155.5m (loss narrowed 14% from FY 2022). Revenue missed analyst estimates by 9.3%. Earnings per share (EPS) also missed analyst estimates by 3.6%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in the US.お知らせ • Mar 26Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million.Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $1 Discount Per Security: $0.07 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,750,000 Price\Range: $0.9999 Discount Per Security: $0.06993 Transaction Features: Registered Direct OfferingNew Risk • Mar 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$92m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding).お知らせ • Mar 21Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million.Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,000,000 Price\Range: $1 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Price\Range: $1.33 Transaction Features: Registered Direct OfferingNew Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$92m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Market cap is less than US$100m (US$91.8m market cap).お知らせ • Jan 31Danimer Scientific Receives Continued Listing Standard Notice from NYSEDanimer Scientific, Inc. announced that it received a notice from the New York Stock Exchange ('NYSE') on January 23, 2024, that the Company is not currently in compliance with the NYSE's continued listing standard requiring listed-company stock to maintain an average closing price of not less than $1.00 per share over a period of thirty (30) consecutive trading days. The Notice does not result in the immediate delisting of the Company's Common Stock from the NYSE. On January 26, 2024, the Company notified the NYSE that it intends to cure the stock price deficiency and return to compliance with the NYSE's minimum share price standard within the six-month period following receipt of the Notice. The Company's Common Stock will continue to be listed and trade on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. The Company intends to consider all available options to cure its non-compliance with the NYSE minimum share price standard. The Company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day periods ending on the last trading day of that month.お知らせ • Jan 19Danimer Scientific, Inc. Announces New DirectorsDanimer Scientific, Inc. announced that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer’s Board of Directors. Dr. Moody’s appointment is effective immediately, and Mr. Altice’s appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the medical, industrial and consumer markets. Dr. Moody previously served as Chief Executive Officer of Jadex from March 2021 through July 2023, and before that served in various roles of increasing responsibility at Milliken & Company culminating in the role of Executive Vice President and Division President, Chemicals. Dr. Moody has over thirty years’ experience managing chemical and polymer related businesses in various leadership roles and holds a Bachelor of Science in Chemistry from Wofford College and a Ph.D. in Chemistry from the Georgia Institute of Technology. Richard N. Altice most recently retired from NatureWorks, a developer and manufacturer of biopolymers (polylactic acid), where he served as President and CEO for five years. Prior to NatureWorks, Mr. Altice was the Senior Vice President and President of PolyOne’s Designed Structures and Solutions, a polymer and plastics converting and food packaging business, formerly known as Spartech. Additionally, Mr. Altice was Vice President of Hexion’s Global Specialty Epoxy resin business and was formerly the President of Solutia’s Technical Specialties division, responsible for the global rubber chemicals and specialty fluids businesses. Mr. Altice has over thirty years of sales, marketing, operational and management experience in the specialty chemicals and biopolymer industries and holds a Bachelor of Science in Chemical Engineering from the Missouri University of Science and Technology. With these changes, Danimer’s Board will be comprised of eleven directors.Recent Insider Transactions • Nov 30Independent Director recently bought US$93k worth of stockOn the 28th of November, Richard Hendrix bought around 100k shares on-market at roughly US$0.93 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$92m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$98.6m market cap).Major Estimate Revision • Nov 24Consensus revenue estimates fall by 21%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$67.5m to US$53.5m. Forecast losses increased from -US$1.38 to -US$1.47 per share. Chemicals industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$4.40 to US$3.10. Share price fell 22% to US$1.11 over the past week.Price Target Changed • Nov 18Price target decreased by 11% to US$4.20Down from US$4.70, the current price target is an average from 5 analysts. New target price is 194% above last closing price of US$1.43. Stock is down 45% over the past year. The company is forecast to post a net loss per share of US$1.53 next year compared to a net loss per share of US$1.78 last year.お知らせ • Nov 08Danimer Scientific, Inc. to Report Q3, 2023 Results on Nov 14, 2023Danimer Scientific, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023お知らせ • Oct 20Danimer Scientific, BIOLO and Bolthouse Farms Announce Commercialization of Home Compostable Packaging for Fresh Produce with Meijer StoresDanimer Scientific, Inc. announced the commercialization of home compostable retail packaging for vegetables and fruit, which Danimer developed in partnership with biodegradable packaging and food service product manufacturer BIOLO and carrot producer Bolthouse Farms. Danimer’s signature PHA, Nodax®, was used to create the bags for one-pound Earthbound Farm Organic Mini Peeled Carrots, now available in Meijer’s regional network of 240 grocery stores and supercenters in six states across the Midwest. Danimer’s Nodax® is a biobased polyester made with oils derived from the seeds of plants such as canola. Unlike traditional plastic, which can take centuries to degrade, Danimer’s PHA-based products can degrade in a matter of months under certain conditions. The Earthbound Farm Organic Mini Peeled Carrots bags are certified as home compostable by TUV, a globally recognized leader in independent product testing, inspection and certification. This certification means that the bags have passed rigorous testing that requires them to disintegrate at least 90% within 26 weeks and biodegrade within 52 weeks under home compost conditions.お知らせ • Aug 01Danimer Scientific, Inc. to Report Q2, 2023 Results on Aug 08, 2023Danimer Scientific, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023お知らせ • May 04Danimer Scientific, Inc. to Report Q1, 2023 Results on May 10, 2023Danimer Scientific, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 10, 2023決済の安定と成長配当データの取得安定した配当: DNMR.Qの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DNMR.Qの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Danimer Scientific 配当利回り対市場DNMR.Q 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DNMR.Q)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Chemicals)1.7%アナリスト予想 (DNMR.Q) (最長3年)n/a注目すべき配当: DNMR.Qは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DNMR.Qは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DNMR.Qの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DNMR.Qが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/06/10 07:43終値2025/06/10 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Danimer Scientific, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Laurence AlexanderJefferies LLC
お知らせ • Apr 18+ 1 more updateBidding Procedure Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the bidding procedures relating to the sale of the substantially all the assets of Danimer Scientific, Inc. on April 17, 2025. The Court approved for the sale of substantially all the assets to the successful bidder through auction. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. If the debtor receives any qualified bids, then it would hold an auction for its assets on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.
お知らせ • Apr 15Motion for sale of De Minimis Asset Sale Approved for Danimer Scientific, Inc.The US Bankruptcy Court gave an order approving the sale procedures relating to the sale of De Minimis assets of Danimer Scientific, Inc on April 14, 2025. As per the order the debtors is authorized to sell de minimis assets for $0.25 million or less in total consideration or value in one or a series of related transactions without further notice or court approval after providing notice of the sale to certain parties in accordance with the following procedures. With regard to a De Minimis transaction with a net selling price less than or equal to $2 million, the debtor shall give written notice of each de Minimis transaction to notice parties. The sale notice shall be filed and sent to the notice parties by e-mail, facsimile, or first-class mail at least 7 business days prior to the closing of such de Minimis transaction. With regard to a De Minimis Transaction with a selling price of greater than $2 million, the debtor shall give a sale notice to the notice parties and all other parties required receiving notice under Bankruptcy Rule 2002(a) (2). The sale notice shall be filed and sent to the 2002 parties by e-mail, facsimile, or first-class mail at least 7 calendar days prior to the closing of such de Minimis transaction. Any objections to the De Minimis Transaction must be in writing, state the grounds for the objection with specificity, and be filed and served so as to be actually received on or before the Closing Date. If a sale objection is properly filed and served by the sale objection deadline, and the debtor and the objecting party are unable to reach an agreement among themselves, then the relevant de Minimis asset shall be sold or otherwise transferred only upon further order of this court, after notice and a hearing; provided, however, that the debtor, with the agreement of the relevant proposed counterparty, may consummate any portion of the de Minimis transaction that is not the subject of a sale objection on or after the expiration of the sale objection deadline. If no sale objection is properly filed and served by the sale objection deadline, then the debtor, without further order of the court, is authorized, but not directed, to consummate the de Minimis transaction immediately, and take such other actions as necessary to close such transaction and collect the proceeds thereof.
お知らせ • Mar 28Motion for Asset Sale Filed by Danimer Scientific, Inc.Danimer Scientific, Inc filed a motion in the US Bankruptcy Court for the sale of its substantially all its assets on March 27, 2025. The debtor seeks the Court’s approval for the sale of its substantially all its assets to successful bidder. To qualify as a qualified bidder, interested parties should submit their bids by May 2, 2025, along with good-faith deposit in the amount of 10% of the bid price. The initial minimum overbid should be at least $0.5 million. The debtor has scheduled an auction on May 5, 2025. At the auction, the subsequent bids would be in increments of $0.5 million. The stalking horse bidder would be entitled to a break-up fee of 3%. The sale hearing is scheduled for May 12, 2025. Sale closing is on May 16, 2025.
お知らせ • Mar 19+ 1 more updateMotion for Joint Administration Filed by Danimer Scientific, Inc.Danimer Scientific, Inc., along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on March 18, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Danimer Bioplastics, Inc., Danimer Scientific Holdings, LLC, Danimer Scientific Kentucky, Inc., Danimer Scientific Manufacturing, Inc., Danimer Scientific, L.L.C. Meredian Bioplastics, Inc., Meredian Holdings Group, Inc., Meredian, Inc. and Novomer, Inc., with its own case for administrative and procedural purposes. Danimer Scientific, Inc. has been proposed as the lead debtor.
お知らせ • Dec 18Danimer Scientific, Inc. announced that it expects to receive $11.25 million in fundingDanimer Scientific, Inc. announced that it has entered into a super senior secured uninsured promissory note agreement with certain lenders under its existing term loan financing agreement, as well as certain additional lenders for a secured loan for a principal amount of $11,250,000 in exchange for cash, net of a 5% upfront fee and other fees and expenses on December 17, 2024. The secured loan matures on December 17, 2026, and accrues interest at 15% per annum, which interest shall be paid in kind on a quarterly basis. Prepayment of the secured loan is subject to payment of premiums of (i) prior to December 17, 2025, 30% and (ii) on or after December 17, 2025, and before maturity, 10%.
お知らせ • Dec 04Danimer Scientific, Inc. Announces Resignation of Cynthia Cohen as A DirectorDanimer Scientific, Inc. announced that effective as of December 1, 2024, Cynthia Cohen resigned as a director of the Company. Ms. Cohen’s resignation was not because of any disagreement with the Company.
お知らせ • Nov 16Danimer Scientific, Inc. announced delayed 10-Q filingOn 11/15/2024, Danimer Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 05Danimer Scientific Announces Intention to Complete a Reverse Stock Split to Regain Compliance with the Price Criteria of Section 802.01C of the NYSE Listed Company ManualDanimer Scientific, Inc. announced that, following approval by the Company's stockholders and its Board of Directors, the Company will effect a reverse stock split ('Reverse Stock Split') of Danimer's Class A common stock, par value $0.0001 per share ('Common Stock'), at a ratio of 1-for-40 (the 'Reverse Stock Split Ratio'), which ratio was determined by the Board of Directors from within a range of ratios authorized by the stockholders. The Reverse Stock Split is expected to become effective on November 12, 2024, after close of trading on the New York Stock Exchange ('NYSE'). The Common Stock is expected to begin trading on a split-adjusted basis when the markets open on November 13, 2024, under the existing trading symbol 'DNMR' and new CUSIP number (236272 407). The Company believes the Reverse Stock Split will increase the price per share of the Common Stock and thus enable it to regain compliance with the price criteria of Section 802.01C of the NYSE Listed Company Manual (the 'Minimum Share Price Rule').
Board Change • Nov 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Special Advisor & Director Stephen Croskrey was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 28Danimer Scientific Announces Second Circuit Court Affirms Dismissal of Class Action LawsuitDanimer Scientific, Inc. announced that, on September 27, 2024, the United States Court of Appeals for the Second Circuit affirmed the 2023 Order of the United States District Court for the Eastern District of New York dismissing a previously disclosed putative class action complaint captioned In re Danimer Scientific, Inc. Securities Litigation. Subsequently, the plaintiffs in the three shareholder derivative cases that had been pending in state and federal courts in Delaware, which cases had been stayed pending the outcome of the Second Circuit case, dismissed their complaints.
お知らせ • Oct 15+ 2 more updatesDanimer Scientific, Inc. to Report Q3, 2024 Results on Nov 14, 2024Danimer Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 14, 2024
Price Target Changed • Sep 14Price target decreased by 25% to US$0.85Down from US$1.13, the current price target is an average from 4 analysts. New target price is 115% above last closing price of US$0.40. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.81 next year compared to a net loss per share of US$1.52 last year.
New Risk • Sep 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$66m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$59m net loss in 3 years). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (US$39.7m market cap).
Major Estimate Revision • Aug 15Consensus revenue estimates decrease by 44%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$74.0m to US$41.7m. EPS estimate increased from -US$0.885 to -US$0.785 per share. Chemicals industry in the US expected to see average net income growth of 40% next year. Consensus price target down from US$1.41 to US$1.13. Share price fell 20% to US$0.37 over the past week.
Price Target Changed • Aug 12Price target decreased by 12% to US$1.33Down from US$1.51, the current price target is an average from 5 analysts. New target price is 237% above last closing price of US$0.39. Stock is down 82% over the past year. The company is forecast to post a net loss per share of US$0.79 next year compared to a net loss per share of US$1.52 last year.
Reported Earnings • Aug 09Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: US$0.20 loss per share (improved from US$0.39 loss in 2Q 2023). Revenue: US$7.63m (down 41% from 2Q 2023). Net loss: US$22.7m (loss narrowed 42% from 2Q 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 17%. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in the US.
お知らせ • Aug 09Danimer Scientific, Inc. Provides Financial Guidance for the Second Quarter of Fiscal 2025Danimer Scientific, Inc. provides financial guidance for the second quarter of fiscal 2025. For the period, the company expects annualized PHA revenues to more than triple, based solely on demand from existing customer relationships and their indicated volumes, including the aforementioned 20-million-pound cutlery award.
お知らせ • Aug 02Danimer Scientific, Inc. to Report Q2, 2024 Results on Aug 08, 2024Danimer Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024
お知らせ • Jun 13+ 14 more updatesDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value IndexDanimer Scientific, Inc.(UNQ:) dropped from Russell 2000 Value Index
お知らせ • May 25Danimer Scientific, Inc. Receives Non-Compliance Notice from NYSE RegulationOn May 21, 2024, Danimer Scientific, Inc. (the Company") was notified by NYSE Regulation (NYSER") that the Company is not in compliance with the New York Stock Exchange's (NYSE") continued listing criteria under Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period as of May 20, 2024. The Company has notified the NYSE of its intent to cure the deficiency and return to compliance with the NYSE continued listing requirements. The Company will return to compliance if, during the six-month period following receipt of the NYSE notice, on the last trading-day of any calendar month, the Company's common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under NYSE rules, the Company's common stock will continue to be traded on the NYSE during this period, subject to the Company's compliance with other applicable continued listing requirements. The NYSER notification does not affect the Company's business operations, Securities and Exchange Commission reporting requirements or debt obligations.
Price Target Changed • May 22Price target decreased by 10% to US$1.41Down from US$1.57, the current price target is an average from 5 analysts. New target price is 84% above last closing price of US$0.76. Stock is down 75% over the past year. The company is forecast to post a net loss per share of US$0.89 next year compared to a net loss per share of US$1.52 last year.
分析記事 • May 21News Flash: Analysts Just Made A Substantial Upgrade To Their Danimer Scientific, Inc. (NYSE:DNMR) ForecastsShareholders in Danimer Scientific, Inc. ( NYSE:DNMR ) may be thrilled to learn that the analysts have just delivered a...
Major Estimate Revision • May 14Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$78.3m to US$60.9m. Forecast losses increased from -US$0.91 to -US$0.92 per share. Chemicals industry in the US expected to see average net income growth of 34% next year. Consensus price target of US$1.51 unchanged from last update. Share price was steady at US$0.80 over the past week.
分析記事 • May 10Danimer Scientific, Inc. (NYSE:DNMR) Analysts Are Cutting Their Estimates: Here's What You Need To KnowDanimer Scientific, Inc. ( NYSE:DNMR ) shareholders are probably feeling a little disappointed, since its shares fell...
New Risk • May 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$68m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$68m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (US$93.7m market cap).
Reported Earnings • May 08First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: US$0.26 loss per share (improved from US$0.36 loss in 1Q 2023). Revenue: US$10.2m (down 14% from 1Q 2023). Net loss: US$27.3m (loss narrowed 26% from 1Q 2023). Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 1.3%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Chemicals industry in the US.
お知らせ • May 07Danimer Scientific Reveals New Branding and New Applications Based on PHA During NPE 2024Danimer Scientific, Inc. is unveiling new commercial applications and branding during NPE 2024, North America’s large plastics tradeshow, taking place this week in Orlando, FL. A more perfect polymer™ takes center stage at NPE 2024. Danimer’s signature PHA, Nodax®, represents a more perfect polymer revolution. PHAs (polyhydroxyalkanoates) are naturally made polymer chains, and at Danimer it harness microbes as tiny reactors to make its biopolymers, using canola oil as the renewable feedstock. The resulting PHA can be used to replace conventional plastics in uses from straws to lids, from coffee pods to flexible packaging, and from paper coatings to adhesives. With full PHA production capability in place, Danimer is poised for significant growth with commercial partners for several applications, including cutlery, flexible food packaging and paper packaging barrier coatings. Microbes, not Microplastics™ enables a new future for packaging items. Danimer is committed to offering solutions to address plastic pollution and the proliferation of microplastics. It is all about the microbes, both during origination and biodegradation. Microbes produce PHAs, and microbes biochemically recycle its PHAs, whether in industrial compost, home compost, soils, fresh water or the marine environment. Because a large class of microbes present in natural systems readily identify PHAs as a food source, there is no threat of residual microplastics. PHA grades are third party certified to fully biodegrade under various conditions, with the added benefit of no ecotoxicity concerns, PFAS or regulated metals. That makes Nodax a more perfect polymer™ for its planet.
お知らせ • May 05Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024Danimer Scientific, Inc., Annual General Meeting, Jul 09, 2024.
お知らせ • May 03Danimer Scientific, Inc. to Report Q1, 2024 Results on May 07, 2024Danimer Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
分析記事 • Apr 25Broker Revenue Forecasts For Danimer Scientific, Inc. (NYSE:DNMR) Are Surging HigherDanimer Scientific, Inc. ( NYSE:DNMR ) shareholders will have a reason to smile today, with the analysts making...
Major Estimate Revision • Apr 23Consensus revenue estimates increase by 11%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$70.3m to US$78.3m. EPS estimate unchanged from -US$0.91 at last update. Chemicals industry in the US expected to see average net income growth of 27% next year. Consensus price target down from US$1.57 to US$1.51. Share price rose 2.6% to US$0.80 over the past week.
New Risk • Apr 12New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$73m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding). Market cap is less than US$100m (US$98.6m market cap).
Major Estimate Revision • Apr 05Consensus revenue estimates decrease by 25%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$95.8m to US$72.0m. EPS estimate increased from -US$1.42 to -US$0.81 per share. Chemicals industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$2.57 to US$2.02. Share price fell 3.7% to US$1.05 over the past week.
Price Target Changed • Apr 02Price target decreased by 14% to US$2.22Down from US$2.57, the current price target is an average from 5 analysts. New target price is 109% above last closing price of US$1.06. Stock is down 76% over the past year. The company is forecast to post a net loss per share of US$1.16 next year compared to a net loss per share of US$1.52 last year.
Reported Earnings • Apr 01Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$1.52 loss per share (improved from US$1.78 loss in FY 2022). Revenue: US$46.7m (down 12% from FY 2022). Net loss: US$155.5m (loss narrowed 14% from FY 2022). Revenue missed analyst estimates by 9.3%. Earnings per share (EPS) also missed analyst estimates by 3.6%. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in the US.
お知らせ • Mar 26Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million.Danimer Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $14.999625 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,250,000 Price\Range: $1 Discount Per Security: $0.07 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 3,750,000 Price\Range: $0.9999 Discount Per Security: $0.06993 Transaction Features: Registered Direct Offering
New Risk • Mar 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$92m net loss in 3 years). Shareholders have been diluted in the past year (12% increase in shares outstanding).
お知らせ • Mar 21Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million.Danimer Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $34.95 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,000,000 Price\Range: $1 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 15,000,000 Price\Range: $1.33 Transaction Features: Registered Direct Offering
New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$92m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Market cap is less than US$100m (US$91.8m market cap).
お知らせ • Jan 31Danimer Scientific Receives Continued Listing Standard Notice from NYSEDanimer Scientific, Inc. announced that it received a notice from the New York Stock Exchange ('NYSE') on January 23, 2024, that the Company is not currently in compliance with the NYSE's continued listing standard requiring listed-company stock to maintain an average closing price of not less than $1.00 per share over a period of thirty (30) consecutive trading days. The Notice does not result in the immediate delisting of the Company's Common Stock from the NYSE. On January 26, 2024, the Company notified the NYSE that it intends to cure the stock price deficiency and return to compliance with the NYSE's minimum share price standard within the six-month period following receipt of the Notice. The Company's Common Stock will continue to be listed and trade on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. The Company intends to consider all available options to cure its non-compliance with the NYSE minimum share price standard. The Company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period or on the last day of the cure period, the Company has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day periods ending on the last trading day of that month.
お知らせ • Jan 19Danimer Scientific, Inc. Announces New DirectorsDanimer Scientific, Inc. announced that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer’s Board of Directors. Dr. Moody’s appointment is effective immediately, and Mr. Altice’s appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the medical, industrial and consumer markets. Dr. Moody previously served as Chief Executive Officer of Jadex from March 2021 through July 2023, and before that served in various roles of increasing responsibility at Milliken & Company culminating in the role of Executive Vice President and Division President, Chemicals. Dr. Moody has over thirty years’ experience managing chemical and polymer related businesses in various leadership roles and holds a Bachelor of Science in Chemistry from Wofford College and a Ph.D. in Chemistry from the Georgia Institute of Technology. Richard N. Altice most recently retired from NatureWorks, a developer and manufacturer of biopolymers (polylactic acid), where he served as President and CEO for five years. Prior to NatureWorks, Mr. Altice was the Senior Vice President and President of PolyOne’s Designed Structures and Solutions, a polymer and plastics converting and food packaging business, formerly known as Spartech. Additionally, Mr. Altice was Vice President of Hexion’s Global Specialty Epoxy resin business and was formerly the President of Solutia’s Technical Specialties division, responsible for the global rubber chemicals and specialty fluids businesses. Mr. Altice has over thirty years of sales, marketing, operational and management experience in the specialty chemicals and biopolymer industries and holds a Bachelor of Science in Chemical Engineering from the Missouri University of Science and Technology. With these changes, Danimer’s Board will be comprised of eleven directors.
Recent Insider Transactions • Nov 30Independent Director recently bought US$93k worth of stockOn the 28th of November, Richard Hendrix bought around 100k shares on-market at roughly US$0.93 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
New Risk • Nov 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$92m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$98.6m market cap).
Major Estimate Revision • Nov 24Consensus revenue estimates fall by 21%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$67.5m to US$53.5m. Forecast losses increased from -US$1.38 to -US$1.47 per share. Chemicals industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$4.40 to US$3.10. Share price fell 22% to US$1.11 over the past week.
Price Target Changed • Nov 18Price target decreased by 11% to US$4.20Down from US$4.70, the current price target is an average from 5 analysts. New target price is 194% above last closing price of US$1.43. Stock is down 45% over the past year. The company is forecast to post a net loss per share of US$1.53 next year compared to a net loss per share of US$1.78 last year.
お知らせ • Nov 08Danimer Scientific, Inc. to Report Q3, 2023 Results on Nov 14, 2023Danimer Scientific, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
お知らせ • Oct 20Danimer Scientific, BIOLO and Bolthouse Farms Announce Commercialization of Home Compostable Packaging for Fresh Produce with Meijer StoresDanimer Scientific, Inc. announced the commercialization of home compostable retail packaging for vegetables and fruit, which Danimer developed in partnership with biodegradable packaging and food service product manufacturer BIOLO and carrot producer Bolthouse Farms. Danimer’s signature PHA, Nodax®, was used to create the bags for one-pound Earthbound Farm Organic Mini Peeled Carrots, now available in Meijer’s regional network of 240 grocery stores and supercenters in six states across the Midwest. Danimer’s Nodax® is a biobased polyester made with oils derived from the seeds of plants such as canola. Unlike traditional plastic, which can take centuries to degrade, Danimer’s PHA-based products can degrade in a matter of months under certain conditions. The Earthbound Farm Organic Mini Peeled Carrots bags are certified as home compostable by TUV, a globally recognized leader in independent product testing, inspection and certification. This certification means that the bags have passed rigorous testing that requires them to disintegrate at least 90% within 26 weeks and biodegrade within 52 weeks under home compost conditions.
お知らせ • Aug 01Danimer Scientific, Inc. to Report Q2, 2023 Results on Aug 08, 2023Danimer Scientific, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023
お知らせ • May 04Danimer Scientific, Inc. to Report Q1, 2023 Results on May 10, 2023Danimer Scientific, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 10, 2023